United Therapeutics Corporation
UTHR
Clasificación en acciones
#999
United Therapeutics Corporation, a biotechnology firm, is dedicated to... United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Precio por acción
$551.89
Capitalización bursátil
$23.67B
Cambio (1 día)
1.61%
Cambio (1 año)
27.55%
País
US
Comercio United Therapeutics Corporation (UTHR)
Categoría
Healthcare
Ratio P/E de United Therapeutics Corporation (UTHR)
Ratio P/E al October 2026 TTM: 17.86
Según los últimos informes financieros y el precio de las acciones de United Therapeutics Corporation, el P/E actual (TTM) de la empresa es 17.86. Al final de 2023, la empresa tenía un P/E de 10.45.
Historial del ratio P/E de United Therapeutics Corporation desde 2000 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 17.86 | 33.91% |
| 2024 | 13.34 | 27.71% |
| 2023 | 10.45 | -39.94% |
| 2022 | 17.40 | -14.68% |
| 2021 | 20.39 | 56.46% |
| 2020 | 13.03 | -135.30% |
| 2019 | -36.92 | -559.18% |
| 2018 | 8.04 | -48.39% |
| 2017 | 15.58 | 76.97% |
| 2016 | 8.80 | -20.38% |
| 2015 | 11.06 | -39.73% |
| 2014 | 18.34 | -43.45% |
| 2013 | 32.44 | 254.89% |
| 2012 | 9.14 | -26.27% |
| 2011 | 12.40 | -63.01% |
| 2010 | 33.51 | -76.77% |
| 2009 | 144.23 | -530.83% |
| 2008 | -33.48 | -132.08% |
| 2007 | 104.36 | 517.01% |
| 2006 | 16.91 | -30.30% |
| 2005 | 24.27 | -61.78% |
| 2004 | 63.49 | -230.50% |
| 2003 | -48.65 | 233.78% |
| 2002 | -14.58 | 157.39% |
| 2001 | -5.66 | 50.91% |
| 2000 | -3.75 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 28.78 | 61.12% |
US
|
|
| -28.36 | -258.75% |
US
|
|
| -24.57 | -237.52% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 69.78% |
NL
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.